Article
Novartis drug candidate scores interim win in rare kidney disease trial
Rating:
0.0
Views:
57
Likes:
1
Library:
1
Novartis said its experimental drug atrasentan was shown to have a positive effect on an indicator of kidney health in people suffering from a rare type of kidney disease in an interim analysis of a late-stage drug trial.
Rate This Post
Rate The Educational Value
Rate The Ease of Understanding and Presentation
Interesting or Boring? Rate the Entertainment Value